Seelos Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to the discovery, development, and eventual commercialization of innovative therapies. These treatments primarily target central nervous system (CNS), respiratory, and various other medical conditions. The company's pipeline includes several key clinical-stage candidates. Foremost among these is SLS-002, an intranasally administered racemic ketamine, being investigated for rapidly alleviating acute suicidal ideation and behavior in individuals with major depressive disorder (MDD). Another significant program, SLS-005, acts as a protein stabilizer, addressing amyotrophic lateral sclerosis (ALS) and Sanfilippo syndrome. Additionally, SLS-006 is a partial dopamine agonist under development for the treatment of Parkinson's disease (PD). Beyond its clinical efforts, Seelos maintains a robust preclinical portfolio exploring novel mechanisms. This includes SLS-007, an anti-alpha-synuclein peptidic inhibitor designed to combat Parkinson's disease, and SLS-008, an orally bioavailable antagonist targeting chemoattractant receptor-homologous molecule, intended for chronic inflammatory conditions such as asthma and specific pediatric orphan diseases. Other early-stage candidates comprise SLS-004 for Parkinson's disease; SLS-010, an oral histamine H3A receptor antagonist aimed at narcolepsy and related sleep disorders; and SLS-012, an injectable formulation for managing post-operative pain. Founded in 1987, Seelos Therapeutics, Inc. operates from its headquarters situated in New York, New York.